ATE94069T1 - Verwendung von physiologisch wirksamen substanzen zur herstellung von medikamenten fuer gehirn- und nervenerkrankungen. - Google Patents

Verwendung von physiologisch wirksamen substanzen zur herstellung von medikamenten fuer gehirn- und nervenerkrankungen.

Info

Publication number
ATE94069T1
ATE94069T1 AT89810464T AT89810464T ATE94069T1 AT E94069 T1 ATE94069 T1 AT E94069T1 AT 89810464 T AT89810464 T AT 89810464T AT 89810464 T AT89810464 T AT 89810464T AT E94069 T1 ATE94069 T1 AT E94069T1
Authority
AT
Austria
Prior art keywords
manufacture
physiologically active
active substances
brain
medications
Prior art date
Application number
AT89810464T
Other languages
English (en)
Inventor
Jin-Emon Konishi
Pharmaceutical Co Ltd - K Zoki
Original Assignee
Nippon Zoki Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Zoki Pharmaceutical Co filed Critical Nippon Zoki Pharmaceutical Co
Application granted granted Critical
Publication of ATE94069T1 publication Critical patent/ATE94069T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT89810464T 1988-06-20 1989-06-16 Verwendung von physiologisch wirksamen substanzen zur herstellung von medikamenten fuer gehirn- und nervenerkrankungen. ATE94069T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP63152492A JP2539665B2 (ja) 1988-06-20 1988-06-20 神経疾患治療剤
EP89810464A EP0348353B1 (de) 1988-06-20 1989-06-16 Verwendung von physiologisch wirksamen Substanzen zur Herstellung von Medikamenten für Gehirn- und Nervenerkrankungen

Publications (1)

Publication Number Publication Date
ATE94069T1 true ATE94069T1 (de) 1993-09-15

Family

ID=15541651

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89810464T ATE94069T1 (de) 1988-06-20 1989-06-16 Verwendung von physiologisch wirksamen substanzen zur herstellung von medikamenten fuer gehirn- und nervenerkrankungen.

Country Status (6)

Country Link
US (1) US5013558A (de)
EP (1) EP0348353B1 (de)
JP (1) JP2539665B2 (de)
AT (1) ATE94069T1 (de)
DE (1) DE68908971T2 (de)
ES (1) ES2058592T3 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2588109B2 (ja) * 1993-03-19 1997-03-05 日本臓器製薬株式会社 鎮痛剤
JP3213831B2 (ja) * 1993-08-06 2001-10-02 日本臓器製薬株式会社 被検物質の活性測定方法
JP3213832B2 (ja) * 1993-08-06 2001-10-02 日本臓器製薬株式会社 被検物質の活性測定法
JP2594222B2 (ja) * 1993-09-28 1997-03-26 日本臓器製薬株式会社 新規生理活性物質−ｋｆ
JP2732379B2 (ja) * 1995-12-18 1998-03-30 日本臓器製薬株式会社 知覚異常改善剤
US5906976A (en) * 1996-10-22 1999-05-25 Ramot-University Authority For Applied Research And Industrial Development, Ltd. Method and composition for treating neuronal degeneration
JP4033936B2 (ja) * 1997-01-08 2008-01-16 日本臓器製薬株式会社 一酸化窒素産生抑制剤
JPH1180005A (ja) * 1997-09-12 1999-03-23 Nippon Zoki Pharmaceut Co Ltd 骨粗鬆症治療剤
KR19990044835A (ko) 1997-11-28 1999-06-25 고니시 진우에몬 생약추출물
AU2402399A (en) * 1998-04-27 2000-11-02 Nippon Zoki Pharmaceutical Co., Ltd. A therapeutic agent for ischemic diseases
CN1272365A (zh) 1999-04-15 2000-11-08 日本脏器制药株式会社 新型生理活性物质
CN1312080A (zh) 2000-02-18 2001-09-12 日本脏器制药株式会社 含有脂肪酸的组合物
JP2002068973A (ja) * 2000-06-16 2002-03-08 Meiji Milk Prod Co Ltd 幹細胞分化誘導促進剤
US6913900B2 (en) * 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
TWI342778B (en) 2002-10-31 2011-06-01 Nippon Zoki Pharmaceutical Co Therapeutic agent for fibromyalgia
CN1207005C (zh) * 2002-10-31 2005-06-22 威世药业（如皋）有限公司 含生物活性物质的兔皮和其用途
WO2004047871A2 (en) * 2002-11-26 2004-06-10 Nobex Corporation Modified naturetic compounds, conjugates, and uses thereof
WO2005046668A1 (ja) * 2003-11-14 2005-05-26 Mochida Pharmaceutical Co., Ltd. 言語障害予防・治療剤
EP3372614B1 (de) * 2004-04-07 2022-06-08 Rinat Neuroscience Corp. Verfahren zur schmerzbehandlung in knochenkrebs durch verabreichung eines ngf-antagonististen
EP1773857A4 (de) * 2004-07-02 2009-05-13 Protiva Biotherapeutics Inc Das immunsystem stimulierende sirna-moleküle und anwendungen davon
KR101307999B1 (ko) * 2004-12-01 2013-09-12 니폰 조키 세야쿠 가부시키가이샤 건조물 및 그 제조방법
US20060134646A1 (en) * 2004-12-17 2006-06-22 Ansari Aftab A Method for treatment of HIV infection
US20060194723A1 (en) * 2005-02-28 2006-08-31 Rabinoff Michael D Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement
TWI406664B (zh) 2006-03-30 2013-09-01 Univ Kyoto 硫氧還蛋白（ｔｈｉｏｒｅｄｏｘｉｎ）產生促進劑
US8613962B2 (en) 2007-08-31 2013-12-24 Kyushu University, National University Corporation Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent
CA2721333C (en) * 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
CN101732348B (zh) 2008-11-11 2015-01-14 威世药业（如皋）有限公司 牛痘疫苗致炎兔皮提取物在制备急性脑血管疾病治疗药物中的用途
TWI483729B (zh) 2010-03-11 2015-05-11 Nippon Zoki Pharmaceutical Co 慢性前列腺炎、間質性膀胱炎及／或排尿障礙之改善或治療劑
US9447466B2 (en) 2010-06-25 2016-09-20 Nippon Zoki Pharmaceutical Co., Ltd. Method for determination or evaluation of test substance
KR101894754B1 (ko) 2010-10-14 2018-09-04 니폰 조키 세야쿠 가부시키가이샤 연골세포의 콜라겐 및 프로테오글리칸의 합성 촉진 방법
JP6469002B2 (ja) 2013-04-30 2019-02-13 日本臓器製薬株式会社 抽出物及び該抽出物を含有する製剤
US11129976B2 (en) 2016-02-24 2021-09-28 Osaka University Test method
WO2018056412A1 (ja) 2016-09-23 2018-03-29 国立大学法人大阪大学 シュワン細胞分化促進剤及び末梢神経再生促進剤
KR102732610B1 (ko) * 2017-03-06 2024-11-21 니폰 조키 세야쿠 가부시키가이샤 Aβ-유발 손상에 대한 신경 보호능을 측정하는 방법
EP3918335A4 (de) * 2019-01-30 2022-09-28 Nippon Zoki Pharmaceutical Co., Ltd. Mittel zur hemmung oder linderung von entzündungen im gehirn
EP4506013A4 (de) * 2022-04-01 2026-02-25 Star Bright Bio Tech Ltd Verwendung eines durch vacciniavirus entzündeten extrakts aus kaninchenhaut zur behandlung von morbus parkinson

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53101515A (en) * 1977-02-17 1978-09-05 Nippon Zoki Pharmaceutical Co Medicine having anodyne * sedative and antiallergic activity and production thereof
JPS59118711A (ja) * 1982-12-25 1984-07-09 Nippon Zoki Pharmaceut Co Ltd 新規生理活性物質
JP2539674B2 (ja) * 1987-11-06 1996-10-02 日本臓器製薬株式会社 新規生理活性物質

Also Published As

Publication number Publication date
EP0348353B1 (de) 1993-09-08
JPH01319422A (ja) 1989-12-25
ES2058592T3 (es) 1994-11-01
JP2539665B2 (ja) 1996-10-02
EP0348353A3 (en) 1990-10-31
EP0348353A2 (de) 1989-12-27
DE68908971T2 (de) 1994-01-13
US5013558A (en) 1991-05-07
DE68908971D1 (de) 1993-10-14

Similar Documents

Publication Publication Date Title
ATE94069T1 (de) Verwendung von physiologisch wirksamen substanzen zur herstellung von medikamenten fuer gehirn- und nervenerkrankungen.
DE69331605D1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
ATE271874T1 (de) Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE69230046D1 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
DE69124293D1 (de) Vorrichtung zur Behandlung von Wirbelsäulenerkrankungen
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
ATE394110T1 (de) Isolierte stromalzellen zur verwendung in der behandlung von erkrankungen des zentralnervensystems
NO905264L (no) Fremgangsmaate for fremstilling av biologisk aktivt protein
ATE209908T1 (de) RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
DE3876756D1 (de) Vorrichtung zur gesteuerten freigabe und verabreichung von wirkstoffen an tierisches gewebe.
ATE133859T1 (de) Pharmazeutische zubereitungen mit verzögerter freisetzung zur behandlung periodontaler erkrankungen
ATE76753T1 (de) Pharmazeutische zusammensetzung zur intranasalen verabreichung, die ghrh, einen cholinergischen agonisten und gegebenenfalls ein gallensalz enthaelt.
DE3850154D1 (de) Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression.
DE60018554D1 (de) Arzneimittel zur förderung der neuronalen zelldifferenzierung, die cyclische glycerophosphate und deren analoga enthalten
ATE222491T1 (de) Melatonin-derivate zur verwendung in der behandlung von schlafstörungen
ATE169500T1 (de) Verwendung von guanosin zur herstellung von arzneimitteln zur behandlung von zerebralen funktionsstörungen
ATE316379T1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
DE59304087D1 (de) Placentaextrakt und Verfahren zu seiner Herstellung
RU94006635A (ru) Способ коррекции функциональных состояний
DE3784738D1 (de) Topische vorstufen von arzneimitteln zur behandlung von akne und hautkrankheiten.
DE68901172D1 (de) (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
Gonzalez-Lima Activation of substantia gelatinosa by midbrain reticular stimulation demonstrated with 2-deoxyglucose in the rat spinal cord
DE68909750D1 (de) Vorrichtung zur therapeutischen behandlung von lumbago sowie lumbago/ischias.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee